Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Tissue Regenix’s CellRight signs multi-year distribution agreement with Arthrex Inc.

The regenerative medical devices company said the multi-year commitment will give surgeons access to verified osteobiologics and advanced surgical instruments and techniques to help influence better patient outcomes
X-Ray of knees
CellRight provides osteobiologics for use in orthopaedic, spine and foot, and ankle procedures

Tissue Regenix Group PLC (LON:TRX) shares jumped 6% higher on Tuesday as the firm announced that its subsidiary, CellRight Technologies has signed a long-term, multi-year distribution agreement with Arthrex Inc., a premier orthopaedic surgical solutions company.

The AIM-listed regenerative medical devices company said the multi-year commitment will give surgeons access to verified osteobiologics - materials that help heal bone defects - and advanced surgical instruments and techniques to help influence better patient outcomes.

READ: Tissue Regenix launches new unit as it inks US distribution deal

CellRight provides osteobiologics for use in orthopaedic, spine and foot, and ankle procedures to enhance healing of defects caused by trauma or disease.

Steve Couldwell, Tissue Regenix's chief executive, commented: "This is a flagship distribution agreement for CellRight and the wider Tissue Regenix Group. It highlights the value of strategic partnerships with prestigious companies in this space.”

Jesus Hernandez, chief executive of CellRight, added: "This long-term distribution agreement will allow physicians and patients better access to CellRight's innovative orthobiologics through the Arthrex network".

In late morning trading, Tissue Regenix shares were 6.1% higher at 8.75p.

 -- Adds share price --

View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

Related Articles

Summit
January 25 2018
Interim results for a study on ezutromid revealed a “statistically significant and meaningful” reduction in muscle damage, the company said
t-cell
April 04 2018
£1,000 invested at float two years ago would now be worth just north of £3,500
man on a ventilator
January 24 2018
The share price, 280p a year ago, has tracked the progress the firm has made in the clinic with its lead product Traumakine

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use